Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy
Contributors
Blondon, Marc
Published in
Journal of thrombosis and haemostasis, vol. 11, no. 8, p. 1617-1619Publication date
2013Keywords
- ABO Blood-Group System/metabolism
- Administration, Oral
- Aged
- Alleles
- Case-Control Studies
- Cytochrome P-450 CYP3A/metabolism
- Female
- Gene Frequency
- Genetic Variation
- Hormones/administration & dosage
- Humans
- Middle Aged
- NF-E2-Related Factor 2/metabolism
- Polymorphism, Single Nucleotide
- Postmenopause
- Pulmonary Embolism/blood
- Regression Analysis
- Risk Factors
- Venous Thrombosis/blood
- Washington
UNIGE affiliation entities
UNIGE research groups
Citation (ISO format)
BLONDON, Marc et al. Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy. In: Journal of thrombosis and haemostasis, 2013, vol. 11, n° 8, p. 1617–1619. doi: 10.1111/jth.12309
Main files (1)
Article (Published version)
Identifiers
- PID : unige:89078
- DOI : 10.1111/jth.12309
- PMID : 23734777
